TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of exclusivity for ...

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Merck is heavily reliant on Keytruda. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that the company is excessively dependent on the ...

Discover outperforming stocks and invest smarter with Top Smart ... Despite the lowered price target from $136 to $119 due to risks related to Keytruda’s loss-of-exclusivity and Medicare price ...

directing and scaling research efforts to maximize the long-term value of KEYTRUDA. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies ...

Analyst at TD Cowen said Merck (NSE:PROR)'s valuation would likely bottom out in 2026, two years before Keytruda's U.S. patent expires in 2028. "The story other than Keytruda has not improved ...